Evidence map›Paper›PMID 40654914›Full record

ArticlebioRxiv : the preprint server for biology2025

Gene-based calibration of high-throughput functional assays for clinical variant classification.

Daniel Zeiberg, Malvika Tejura, Abbye E McEwen, Shawn Fayer, Vikas Pejaver, Alan F Rubin, Lea M Starita, Douglas M Fowler, Anne O'Donnell-Luria, Predrag Radivojac

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Daniel ZeibergKhoury College of Computer Sciences, Northeastern University, Boston, MA 02115, USA.ORCID 0000-0002-6919-7572
Malvika TejuraDepartment of Genome Sciences, University of Washington, Seattle, WA 98195, USA.
Abbye E McEwenDepartment of Genome Sciences, University of Washington, Seattle, WA 98195, USA.
Shawn FayerDepartment of Genome Sciences, University of Washington, Seattle, WA 98195, USA.
Vikas PejaverInstitute for Genomic Health and Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Alan F RubinBioinformatics Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia; Department of Medical Biology, University of Melbourne, Melbourne, VIC, Australia.
Lea M StaritaDepartment of Genome Sciences, University of Washington, Seattle, WA 98195, USA.
Douglas M FowlerDepartment of Genome Sciences, University of Washington, Seattle, WA 98195, USA.
Anne O'Donnell-LuriaProgram in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA02142, USA.
Predrag RadivojacKhoury College of Computer Sciences, Northeastern University, Boston, MA 02115, USA.

Funding

The Genome Aggregation Database (gnomAD)U24HG011450 · NHGRI · BROAD INSTITUTE, INC. · PI Mark Joseph Daly, Konrad Karczewski · 2021 to 2026
$22.3M
Broad Institute Mendelian Genomic Research CenterU01HG011755 · NHGRI · BROAD INSTITUTE, INC. · PI Anne O'Donnell-Luria, MICHAEL E TALKOWSKI · 2021 to 2026
$14.6M
The Center for Actionable Variant Analysis; measuring variant function at scaleUM1HG011969 · NHGRI · UNIVERSITY OF WASHINGTON · PI Douglas M Fowler, Lea Starita · 2021 to 2026
$9.9M
Supporting IGVF by modeling genetics, function, and phenotype with machine learningU01HG012022 · NHGRI · NORTHEASTERN UNIVERSITY · PI Predrag Radivojac · 2021 to 2026
$3.4M
New approaches for investigating the causes and consequences of cellular heterogeneityR35GM152106 · NIGMS · UNIVERSITY OF WASHINGTON · PI Douglas M Fowler · 2024 to 2026
$1.8M
Integrative data science approaches for rare disease discovery in health recordsR00LM012992 · NLM · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI PEJAVER, VIKAS RAO · 2022 to 2024
$709k
Integrative data science approaches for rare disease discovery in health recordsK99LM012992 · NLM · UNIVERSITY OF WASHINGTON · PI PEJAVER, VIKAS RAO · 2019 to 2020
$184k
NHGRI NIH HHS U01 HG011755NHGRI NIH HHS U01 HG012022NHGRI NIH HHS U24 HG011450NHGRI NIH HHS UM1 HG011969NIGMS NIH HHS R35 GM152106NLM NIH HHS K99 LM012992NLM NIH HHS R00 LM012992
6 · The paper itself

Abstract

High-throughput functional assays measure the effects of variants on macromolecular function and can aid in reclassifying the rapidly growing number of variants of uncertain significance. Under the current clinical variant classification guidelines, using functional data as a line of evidence to assert pathogenicity relies on determining assay score thresholds that define variants as functionally normal or functionally abnormal. These thresholds are designed to maximize the separation of variants with known clinical effects (benign, pathogenic) and often incorporate expert opinion. However, this approach lacks the rigor of calibration, in which a variant's posterior probability of pathogenicity must be estimated from the raw experimental score and mapped to discrete evidence strengths. To build upon the existing guidelines, we introduce and evaluate a method for calibrating continuous high-throughput functional data as a line of evidence in clinical variant classification. Assay score distributions of synonymous variants and variants appearing in gnomAD for a given functional scoreset are jointly modeled with score distributions of known pathogenic and benign variants using a multi-sample skew normal mixture of distributions. This model is learned using a constrained expectation-maximization algorithm that provably preserves the monotonicity of pathogenicity posteriors and is subsequently used to calculate variant-specific evidence strengths for use in the clinic. Using 24 datasets from 14 genes, we first assess the model's ability to capture assay score distributions. We then demonstrate its potential impact on reclassifying variants by comparing the evidence strengths assigned at the variant-level with those assigned uniformly to all functionally normal and abnormal variants under the existing ClinGen guidelines. An improved classification of variants will directly improve the accuracy of genetic diagnosis and subsequent medical management for individuals affected by Mendelian disorders. Availability: https://github.com/dzeiberg/mave_calibration.

Identifiers

PMID40654914
PMCPMC12248162

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.